Search clinical trials for: influenza, vaccine, A/H5N1, aluminum hydroxide, Vero cell

Total 474576 results

National Institute of Allergy and Infectious Diseases...

Completed

A/H5N1in Adult - Aventis

Influenza

United States
Ology Bioservices
Baxter Innovations GmbH

Completed

H5N1 Vaccine Study in Japanese Adults

H5N1 Influenza

Japan
GlaxoSmithKline

Completed

Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure

Influenza | Influenza Vaccines

United States
Institute of Vaccines and Medical Biologicals,...
Department of Health and Human Services; National Institute of Hygiene and... and other collaborators

Completed

A Safety and Immunogenicity Study of IVACFLU-A/H5N1

Avian Influenza

Vietnam
National Institute of Allergy and Infectious Diseases...

Completed

Open-Label Study of H5 Vaccine in Participants of Protocol 04-077

Influenza

United States
Altimmune, Inc.

Completed

Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.

Influenza A Subtype H5N1 Infection

United States
Gamaleya Research Institute of Epidemiology and...

Completed

The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac

Influenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1

Russian Federation
Ology Bioservices

Completed

Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)

Influenza | Pandemic Influenza

United States
GlaxoSmithKline

Completed

Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age

Influenza | Influenza Vaccines

United States, Thailand, Canada
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of an Intramuscular Pandemic Influenza Vaccine in Adults and the Elderly

Influenza | Orthomyxoviridae Infections

Belgium, United Kingdom
VaxInnate Corporation

Completed

Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49

Influenza

United States
GlaxoSmithKline

Completed

Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years

Influenza

United States, Canada
UMN Pharma Inc.

Completed

Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults

Virus Diseases | Influenza

Japan
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Adults

Influenza | Orthomyxoviridae Infections

Australia
PATH
Institute of Experimental Medicine, Russia; Research Institute of Influenza...

Completed

Immunogenicity of H5N1 Vaccine Following H5N2

Influenza Vaccine

Russian Federation
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects

Pandemic H5N1 Influenza

Poland, Turkey
Novavax
Department of Health and Human Services

Completed

A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1

Influenza (Pandemic)

United States
Novartis Vaccines
Department of Health and Human Services

Completed

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults

Pandemic H5N1 Influenza

United States, Australia, Thailand
National Institute of Allergy and Infectious Diseases...
Johns Hopkins Bloomberg School of Public Health

Completed

Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults

Virus Diseases | Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Experimental AD4-H5-VTN Vaccine in Healthy Volunteers

H5N1 Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza Vaccine

H5N1 Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Prospective Study of AI H5N1 in China

Influenza

China
Emergent BioSolutions

Completed

Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1

Influenza | Bird Flu

United States
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 With or Without Topical Aldara in Healthy Adults

Influenza Immunisation | Avian Influenza

United States
Novartis Vaccines
Department of Health and Human Services

Completed

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects

Pandemic H5N1 Influenza

United States, Australia, New Zealand, Thailand
Novartis Vaccines
Department of Health and Human Services

Completed

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children

Pandemic H5N1 Influenza

United States, Thailand
National Institute of Allergy and Infectious Diseases...
Johns Hopkins Bloomberg School of Public Health

Completed

Single Group Study of the Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults

Virus Diseases | Influenza

United States
Seqirus

Completed

A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine

Influenza, Human

Estonia, Philippines
Ology Bioservices
Baxter Innovations GmbH

Completed

Japanese Pediatric H5N1 Vaccine Study

Influenza

Japan
Ology Bioservices

Completed

Study to Assess Safety of an Inactivated H5N1 Influenza Vaccine Administered in GelVac Nasal Powder to Healthy Young Adults

Phase 1 Safety Study of GelVac Nasal Powder H5N1 Influenza Vaccine

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above

Influenza

Germany
Ology Bioservices

Completed

Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk Groups

Influenza

Austria, Belgium, Finland, Germany, Latvia, Lithuania, Netherlands
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions

Influenza, Human

Germany
National Institute of Allergy and Infectious Diseases...

Completed

H5 Adult - Chiron Study of Bird Flu Vaccine

Influenza

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of a Booster Dose of -H5N1 Influenza Vaccine

Avian Influenza

Italy
Novavax
Department of Health and Human Services

Completed

A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2

Influenza (Pandemic)

United States
Cyclacel Pharmaceuticals, Inc.

Terminated

Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
DynPort Vaccine Company LLC, A GDIT Company

Completed

Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant Botulinum Vaccine A/B in Healthy Adults

RECOMBINANT BOTULINUM VACCINE A/B

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Vaccine for Prevention of Bird Flu

Influenza, Human

United States
National Institute of Allergy and Infectious Diseases...

Completed

H5 Vaccine Alone or With Adjuvant in Healthy Adults

Influenza

United States
VaxInnate Corporation

Completed

Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 Mix and Match With AS03

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Development of Immune Globulin Treatment for Avian Flu

Influenza | Infectious Diseases | Avian Flu

United States
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of Age

Influenza

Germany
Sinovac Biotech Co., Ltd
Centers for Disease Control and Prevention, China

Completed

Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Adolescents

Influenza

China
Sinovac Biotech Co., Ltd
Centers for Disease Control and Prevention, China

Completed

Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Children

Influenza

China
Medicago

Completed

Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases

Canada
GlaxoSmithKline

Completed

Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age

Influenza

Belgium, Italy
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 Mix and Match With MF59

Influenza

United States

Search clinical trials for: influenza, vaccine, A/H5N1, aluminum hydroxide, Vero cell

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations